Overview

A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)

Status:
Terminated
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
A Notch signalling pathway inhibitor study in pediatric and adult patients with relapsed (worsening) or refractory (not responding to treatment) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL).
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.